12 Month Outcomes of the SUCCESS PTA Study show consistent safety and effectiveness in claudicant and CLTI patients when using the SELUTION SLR™ drug eluting balloon.

Dr Michael Lichtenberg (Vascular Centre Clinic Arnsberg, Arnsberg, DE) joins us to discuss the SUCCESS PTA study, a prospective, observational global registry evaluating the SELUTION SLR DEB in 723 patients across Europe, Asia and South America. The primary endpoint was freedom from clinically driven target lesion revascularisation at 12 months, and was consistently high, with clinical improvements in at least one Rutherford category observed across patient cohorts.

Interview Questions:
1. Could you summarise the study?
2. What was the patient population and study design?
3. What were the primary and secondary endpoints?
4. What were the key findings and were there any unexpected results?
5. What could be the clinical impact of these findings?
6. What are the next steps?

Recorded remotely from Arnsberg, 2025.

Editors: Jordan Rance, Yazmin Sadik
Videographers: David Ben-Harosh and Oliver Miles

Support: This is an independent interview produced by Radcliffe Vascular.